Pfizer To Launch Biosimilar Of J&J's Top-Selling Remicade
Drug giant Pfizer Inc. said Monday it will launch a cheaper, biosimilar version of Johnson & Johnson's blockbuster arthritis drug Remicade in late November, raising the stakes in the companies' ongoing...To view the full article, register now.
Already a subscriber? Click here to view full article